BioCryst Pharma (BCRX) Shares Ramp to Session Highs Amid Upcoming Galidesivir Data Presentation

October 26, 2016 2:53 PM EDT

Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.

BioCryst Pharma (NASDAQ: BCRX) shares are ramping to session highs after the company announced that results from a study of galidesivir (formerly BCX4430) administered to Rhesus monkeys infected with Zika virus (ZIKV) will be presented as a late-breaker oral presentation at IDWeek 2016 taking place in New Orleans October 26-30, 2016.

The stock is up around 1.7 percent.

For more color on the announcement, click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Momentum Movers, Trader Talk

Add Your Comment